LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Home・Akciju saraksts・CorMedix Inc

CorMedix Inc

Slēgts

SektorsVeselības aprūpe

11.45 -2.3

Pirkt Pārdot

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

11.45

Max

11.87

Galvenie mērījumi
By Trading Economics
Ienākumi	89M 109M
Pārdošana	65M 104M
P/E Sektora vidējais	5.095 77.671
EPS	0.28
Peļņas marža	104.112
Darbinieki	64
EBITDA	37M 57M

Rekomendācijas
By TipRanks
Rekomendācijas	Pirkt (spēcīgs)
Prognoze 12 mēnešiem	+49.06% upside

Tirgus statistika
By TradingEconomics
Tirgus kapitalizācija	19M 887M
Iepriekšējā atvēršanas cena	13.75
Iepriekšējā slēgšanas cena	11.45

Ziņu noskaņojums

By Acuity

26%

74%

61 / 374 Rangs Healthcare

Tehniskais rādītājs

By Trading Central

Pārliecība

Strong Bullish Evidence

9.2 / N/A Atbalsts un pretestība

CorMedix Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 12. dec. 16:42 UTC

Iegādes, apvienošanās, pārņemšana

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

2025. g. 12. dec. 23:49 UTC

Iegādes, apvienošanās, pārņemšana

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

2025. g. 12. dec. 22:52 UTC

Tirgus saruna

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

2025. g. 12. dec. 22:32 UTC

Peļņas

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025. g. 12. dec. 21:50 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. dec. 20:45 UTC

Peļņas

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

2025. g. 12. dec. 20:41 UTC

Tirgus saruna

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

2025. g. 12. dec. 20:20 UTC

Tirgus saruna

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

2025. g. 12. dec. 19:23 UTC

Peļņas

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

2025. g. 12. dec. 18:35 UTC

Iegādes, apvienošanās, pārņemšana

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

2025. g. 12. dec. 18:33 UTC

Iegādes, apvienošanās, pārņemšana

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

2025. g. 12. dec. 18:31 UTC

Tirgus saruna

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

2025. g. 12. dec. 17:49 UTC

Peļņas

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

2025. g. 12. dec. 17:34 UTC

Iegādes, apvienošanās, pārņemšana

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

2025. g. 12. dec. 17:33 UTC

Iegādes, apvienošanās, pārņemšana

Orange: Closing of the Transaction Is Expected in the First Half of 2026

2025. g. 12. dec. 17:33 UTC

Iegādes, apvienošanās, pārņemšana

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

2025. g. 12. dec. 17:32 UTC

Iegādes, apvienošanās, pārņemšana

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

2025. g. 12. dec. 17:31 UTC

Iegādes, apvienošanās, pārņemšana

Orange to Buy the Stake for EU4.25B in Cash

2025. g. 12. dec. 17:24 UTC

Tirgus saruna

Argentina Predicts Record Wheat Crop -- Market Talk

2025. g. 12. dec. 17:20 UTC

Tirgus saruna

Peļņas

Tech, Media & Telecom Roundup: Market Talk

2025. g. 12. dec. 17:20 UTC

Tirgus saruna

Basic Materials Roundup: Market Talk

2025. g. 12. dec. 17:18 UTC

Tirgus saruna

Peļņas

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

2025. g. 12. dec. 17:09 UTC

Tirgus saruna

Broadcom Investors Were Primed to Sell Shares -- Market Talk

2025. g. 12. dec. 17:09 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 12. dec. 16:47 UTC

Tirgus saruna

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

2025. g. 12. dec. 16:39 UTC

Tirgus saruna

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

2025. g. 12. dec. 16:27 UTC

Iegādes, apvienošanās, pārņemšana

FTC Sues to Block Henkel's $725M Deal for Liquid Nails From PE Firm -- 2nd Update

2025. g. 12. dec. 16:15 UTC

Peļņas

At Costco, Lots of Pie but No Special Dividend. Why the Street Didn't Like the Earnings. -- Barrons.com

2025. g. 12. dec. 15:35 UTC

Peļņas

These Stocks Are Moving the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

2025. g. 12. dec. 14:46 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

CorMedix Inc Prognoze

Cenas mērķis

By TipRanks

49.06% augšup

Prognoze 12 mēnešiem

Vidējais 17.5 USD 49.06%

Augstākais 22 USD

Zemākais 14 USD

Pamatojoties uz 6 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi CorMedix Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

6 ratings

Pirkt

Turēt

Pārdot

Pamatojoties uz 6 analītiķiem, kas pēdējo 3 mēnešu laikā snieguši akciju vērtējumus instrumentam CorMedix Inc — pēdējo 3 mēnešu laikā.

Tehniskais rādītājs

By Trading Central

9.2 / N/AAtbalsts un pretestība

Recent bullish events outweigh bearish events.

All events are bullish.

Noskaņojums

By Acuity

61 / 374 Rangs Veselības aprūpe

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

Par CorMedix Inc

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.